(Reuters) – Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly’s diabetes and weight-loss drugs on its platform.
Shares of the company were up 8.5% in afternoon trading.
The telehealth firm joins its peers such as Teladoc and LifeMD to offer Lilly’s Zepbound ahead of restrictions on selling copies known as compounded drugs.
The company said it will offer both branded versions of Lilly’s tirzepatide – the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro – as well as generics of Novo Nordisk’s diabetes drug, liraglutide.
Hims & Hers previously only offered cheaper versions of Novo’s weight loss drug Wegovy.
(Reporting by Sneha S K in Bengaluru; Editing by Arun Koyyur and Leroy Leo)
Comments